Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06252675 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

StatusRecruiting
PhasePhase 2
Started2024-06-11
View on ClinicalTrials.gov ↗
This phase II trial tests the safety and effectiveness of glofitamab given in combination with pirtobrutinib in treating patients with mantle cell lymphoma that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Glofitamab and obinutuzumab are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Obinutuzumab may also reduce the risk of immune-related conditions from treatment. Pirtobrutinib is in a class of medications called kinase inhibitors. It works by blocking the action of the protein that signals cancer cells to multiply. Giving glofitamab in combination with pirtobrutinib may be safe, tolerable and/or effective in treating patients with relapsed or refractory mantle cell lymphoma.

Amendment record

Amended 10 times since 2024-02-08; most recent filed 2026-07-22. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-31.

2026-07-22
Amendment Study Status, Contacts/Locations v10
2026-04-15
Amendment Study Status, Oversight, Contacts/Locations v9
2025-10-20
Amendment Study Status, Sponsor/Collaborators, Contacts/Locations v8
2025-09-26
Amendment Study Status, Contacts/Locations v7
2025-07-21
Amendment Study Status, Study Description, Arms and Interventions, Outcome Measures, Eligibility v6
2025-05-05
Amendment Study Status, Oversight, Contacts/Locations v5
2025-02-05
Amendment Suspended→Recruiting Study Identification, Study Status, Oversight, Contacts/Locations v4
2024-11-15
Amendment Recruiting→Suspended Study Identification, Study Status, Oversight, Study Design, Contacts/Locations v3
2024-06-21
Amendment Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
2024-04-01
Amendment Study Status v1
2024-02-08
Original filing
Trial Details
NCT Number NCT06252675
Lead Sponsor University of California, San Francisco
Collaborators: Eli Lilly and Company, Genentech, Inc., Adaptive Biotechnologies
Conditions Mantle Cell Lymphoma
Enrollment 30 participants
Start Date 2024-06-11
Primary Completion 2028-07-31 (estimated)
Study Completion 2028-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-24